Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Fry Website

Terry J. Fry, M.D.

Selected Publications

1)  Donahue RN, Duncan BB, Fry TJ, Jones B, Bachovchin WW, Kiritsy CP, Lai JH, Wu W, Zhao P, Liu Y, Tsang K, Hodge JW.
A pan inhibitor of DASH family enzymes induces immunogenic modulation and sensitizes murine and human carcinoma cells to antigen-specific cytotoxic T lymphocyte killing: implications for combination therapy with cancer vaccines.
Vaccine. [Epub ahead of print], 2014.
[Journal]
2)  Shand JC, Qin H, Nasholm N, Capitini CM, Fry TJ.
Minor antigen distribution predicts site-specific graft-versus-tumor activity of adoptively transferred, minor antigen-specific CD8 T Cells.
Biol. Blood Marrow Transplant. 20: 26-36, 2014.
[Journal]
3)  Duncan BB, Highfill SL, Qin H, Bouchkouj N, Larabee S, Zhao P, Woznica I, Liu Y, Li Y, Wu W, Lai JH, Jones B, Mackall CL, Bachovchin WW, Fry TJ.
A Pan-Inhibitor of DASH Family Enzymes Induces Immune-mediated Regression of Murine Sarcoma and Is a Potent Adjuvant to Dendritic Cell Vaccination and Adoptive T-cell Therapy.
J. Immunother. 36: 400-11, 2013.
[Journal]
4)  Capitini CM, Nasholm NM, Duncan BB, Guimond M, Fry TJ.
Graft-versus-host disease impairs vaccine responses through decreased CD4+ and CD8+ T cell proliferation and increased perforin-mediated CD8+ T cell apoptosis.
J. Immunol. 190: 1351-9, 2013.
[Journal]
5)  Fry TJ, Mackall CL.
T-cell adoptive immunotherapy for acute lymphoblastic leukemia.
Hematology Am Soc Hematol Educ Program. 2013: 348-53, 2013.
[Journal]
6)  Walsh MP, Duncan B, Larabee S, Krauss A, Davis JP, Cui Y, Kim SY, Guimond M, Bachovchin W, Fry TJ.
Val-BoroPro Accelerates T Cell Priming via Modulation of Dendritic Cell Trafficking Resulting in Complete Regression of Established Murine Tumors.
PLoS ONE. 8: e58860, 2013.
[Journal]
7)  Salit RB, Fowler DH, Wilson WH, Dean RM, Pavletic SZ, Dunleavy K, Hakim F, Fry TJ, Steinberg SM, Hughes TE, Odom J, Bryant K, Gress RE, Bishop MR.
Dose-adjusted EPOCH-rituximab combined with fludarabine provides an effective bridge to reduced-intensity allogeneic hematopoietic stem-cell transplantation in patients with lymphoid malignancies.
J. Clin. Oncol. 30: 830-6, 2012.
[Journal]
8)  Shah NN, Bacher U, Fry T, Calvo KR, Stetler-Stevenson M, Arthur DC, Kurlander R, Baird K, Wise B, Giralt S, Bishop M, Hardy NM, Wayne AS.
Myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation: diagnostic and therapeutic challenges.
Am. J. Hematol. 87: 916-22, 2012.
[Journal]
9)  Baird K, Fry TJ, Steinberg SM, Bishop MR, Fowler DH, Delbrook CP, Humphrey JL, Rager A, Richards K, Wayne AS, Mackall CL.
Reduced-Intensity Allogeneic Stem Cell Transplantation in Children and Young Adults with Ultrahigh-Risk Pediatric Sarcomas.
Biol Blood Marrow Transplant. 18: 698-707, 2012.
[Journal]
10)  Dubrovsky L, McCarter RJ, Fry TJ, Wong E, Cheng Y, Perez-Albuerne ED.
Analysis of pediatric autologous PBSC apheresis and transplant: Age is a major factor affecting post-transplant toxicity.
Pediatr Blood Cancer. 59: 301-5, 2011.
[Journal]
Click Here to View Expanded Bibliography.

This page was last updated on 4/28/2014.